Stiff-Person Syndrome
The Neurologist 10:131-137, Murinson,B.B., 2004
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients with Standard Surgical Risk
JAMA Neurol 80:437-444,435, Liang,P.,et al, 2023
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People with Antiphospholipid Syndrome
Stroke 49:e41-e42, Bala, M.M.,et al, 2018
Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014
Tumor Necrosis Factor-Alpha Inhibitors: Risk of Malignancy
UpToDate January, Stone, J.H., 2013
The Eye of the Beholder: Inter-rater Agreement among Experts on Psychogenic Jerky Movement Disorders
JNNP 84:742-747, Van de Salm, S.,et al, 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine
Neurol 76:1780-1781, Tong, D., 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
PANDAS
www.medlink.com,Feb, Erfe,M.C.B., 2011
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
A Systematic Review of Outcomes in Patients With Staged Carotid Artery Stenting and Coronary Artery Bypass Graft Surgery
Stroke 39:361-365, Guzman,L.A.,et al, 2008
Botulinum Toxin Type A for the Treatment of Headache: Why We Say Yes
Arch Neurol 65:146-149,151, Ashkenazi,A. &Silberstein,S., 2008
Headache Therapy With Botulinum Toxin: Form Over Substance
Arch Neurol 65:149-151,151, Pakalnis,A. &Couch,J., 2008
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Management of Antiphospholipid Antibody Syndrome, A Systematic Review
JAMA 295:1050-1057, Lim,W.,et al, 2006
ADHD Drugs and Cardiovascular Risk
NEJM 354:1445-1448, Nissen,S.E., 2006
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
Neurophysiologic Analysis of Neuromuscular Symptoms in UK Gulf War Veterans
Neurol 59:1518-1525,1484, Sharief,M.K.,et al, 2002
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Critical Illness Myopathy
Muscle Nerve 23:1785-1788, Lacomis,D.,et al, 2000
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
The Therapeutic Dilemma of Inclusion Body Myositis
Neurol 48:567-568, Barohn,R.J., 1997
How Should a Patient Presenting with Unstable Angina and a Recent Stroke be Managed?
BMJ 310:1449-1452, Davenport,R.J.,et al, 1995
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992